NAPROXEN SODIUM Drug Patent Profile

When do Naproxen Sodium patents expire, and what generic alternatives are available?

Naproxen Sodium is a drug marketed by Bionpharma, Catalent, Onesource Specialty, Patheon Softgels, Puracap Pharm Llc, Actavis Labs Fl Inc, Able, Amneal Pharms Ny, Aurobindo Pharma Ltd, Contract Pharmacal, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Granules India, Hamilton Pharms, Hetero Labs Ltd V, Hikma, Ivax Sub Teva Pharms, Lnk Intl Inc, Marksans Pharma, Novelgenix Theraps, Perrigo, Pharmobedient, Pld Acquisitions Llc, Pliva, Purepac Pharm, Roxane, Sandoz, Sciegen Pharms, Sun Pharm Inds Ltd, Teva, Teva Pharms, Watson Labs, Yichang Humanwell, Amneal Pharms Co, Corepharma, Granules, P And L, Perrigo R And D, and Aurobindo Pharma. and is included in forty-eight NDAs. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has fifteen patent family members in thirteen countries.

The generic ingredient in NAPROXEN SODIUM is naproxen sodium; pseudoephedrine hydrochloride. There are forty-two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the naproxen sodium; pseudoephedrine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Naproxen Sodium

A generic version of NAPROXEN SODIUM was approved as naproxen sodium; pseudoephedrine hydrochloride by PERRIGO on March 17^th, 2004.

Summary for NAPROXEN SODIUM

International Patents:	15
US Patents:	5
Applicants:	40
NDAs:	48
Finished Product Suppliers / Packagers:	121
Raw Ingredient (Bulk) Api Vendors:	93
Clinical Trials:	107
Drug Prices:	Drug price information for NAPROXEN SODIUM
Drug Sales Revenues:	Drug sales revenues for NAPROXEN SODIUM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NAPROXEN SODIUM
What excipients (inactive ingredients) are in NAPROXEN SODIUM?	NAPROXEN SODIUM excipients list
DailyMed Link:	NAPROXEN SODIUM at DailyMed

See drug prices for NAPROXEN SODIUM

See drug sales revenues for NAPROXEN SODIUM

Recent Clinical Trials for NAPROXEN SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Oklahoma	PHASE4
University of Chicago	PHASE4
Endeavor Health	PHASE4

See all NAPROXEN SODIUM clinical trials

Pharmacology for NAPROXEN SODIUM

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for NAPROXEN SODIUM

G02CC	Antiinflammatory products for vaginal administration
G02C	OTHER GYNECOLOGICALS
G02	OTHER GYNECOLOGICALS
G	Genito-urinary system and sex hormones

M01AE	Propionic acid derivatives
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M	Musculo-skeletal system

M02AA	Antiinflammatory preparations, non-steroids for topical use
M02A	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M02	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M	Musculo-skeletal system

Paragraph IV (Patent) Challenges for NAPROXEN SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NAPROXEN SODIUM	Capsules	naproxen sodium	200 mg	021920	1	2017-11-15

US Patents and Regulatory Information for NAPROXEN SODIUM

NAPROXEN SODIUM is protected by eight US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Granules	NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE	diphenhydramine hydrochloride; naproxen sodium	TABLET;ORAL	213663-001	Sep 24, 2020		OTC	No	No
Novelgenix Theraps	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	207612-001	Nov 16, 2018		DISCN	No	No
Hamilton Pharms	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	074106-001	Aug 31, 1993		DISCN	No	No
Purepac Pharm	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	074319-002	Mar 20, 1995		DISCN	No	No
Teva	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	074198-001	Dec 21, 1993		DISCN	No	No

Expired US Patents for NAPROXEN SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bionpharma	NAPROXEN SODIUM	naproxen sodium	CAPSULE;ORAL	021920-001	Feb 17, 2006	11,090,280
Bionpharma	NAPROXEN SODIUM	naproxen sodium	CAPSULE;ORAL	021920-001	Feb 17, 2006	10,022,344
Bionpharma	NAPROXEN SODIUM	naproxen sodium	CAPSULE;ORAL	021920-001	Feb 17, 2006	9,693,978
Bionpharma	NAPROXEN SODIUM	naproxen sodium	CAPSULE;ORAL	021920-001	Feb 17, 2006	9,693,979
Bionpharma	NAPROXEN SODIUM	naproxen sodium	CAPSULE;ORAL	021920-001	Feb 17, 2006	10,028,925

International Patents for NAPROXEN SODIUM

See the table below for patents covering NAPROXEN SODIUM around the world.

Country	Patent Number	Title	Estimated Expiration
Slovenia	1863458
World Intellectual Property Organization (WIPO)	2006096580
Mexico	2007011039	SISTEMA DE SOLVENTE PARA AUMENTAR LA SOLUBILIDAD DE AGENTES FARMACEUTICOS. (SOLVENT SYSTEM FOR ENHANCING THE SOLUBILITY OF PHARMACEUTICAL AGENTS.)
Lithuania	1863458
China	102940887	Solvent system for enhancing the solubility of pharmaceutical agents

Supplementary Protection Certificates for NAPROXEN SODIUM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1411900	18/2011	Austria		PRODUCT NAME: NAPROXEN UND ESOMEPRAZOL SOWIE DEREN PHARMAZEUTISCH ANNEHMBARE SALZE; NAT. REGISTRATION NO/DATE: 1-29937 20110105; FIRST REGISTRATION: GB PL 17901/0263-0001 20101105
1411900	SPC/GB11/015	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0984957	PA2011005	Lithuania		PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
0984957	CR 2012 00035	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
1411900	1190013-1	Sweden		PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105

Naproxen Sodium: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

How big is the naproxen sodium market and where does it sit economically?

Naproxen sodium is a mature, non-prescription and prescription NSAID with long-standing global presence. From a market-structure standpoint, it behaves like a “generic-heavy” oral NSAID platform with periodic branded competitors and recurring volume from chronic indications (osteoarthritis, rheumatoid arthritis, and pain) plus cycling demand around health-system formularies and retail OTC schedules.

Key structural traits drive its market economics:

• Long lifecycle and high generic penetration in most jurisdictions, which compresses brand pricing and elevates distributor and pharmacy share of value.
• Sustained OTC and prescription overlap for pain and inflammation, which supports baseline demand but caps pricing power.
• Cross-NSAID substitution (ibuprofen, diclofenac, ketoprofen, indomethacin, etoricoxib where available), which limits sustained premium unless formulation or channel offers clear differentiation.
• Formulation-led share moves between immediate-release tablets, liquid gels, and extended or enteric-protective variants; naproxen sodium tends to compete on onset/tolerability claims versus conventional naproxen in certain product families.

What product formats and channel dynamics influence revenue for naproxen sodium?

Revenue and volume for naproxen sodium are typically channel- and formulation-dependent.

Dominant formats in trade and consumer demand

• Oral tablets and caplets (most common in both OTC and prescription lines)
• Oral liquid gels (where marketed for faster onset relative to some conventional NSAID forms)
• Combination products (less central than single-entity products, but they affect shelf positioning in some markets)

Channel dynamics that move sales

• OTC retail: price-sensitive, promotional, and pack-size driven. Upsell usually comes from dosing convenience and perceived onset.
• Prescription/health systems: driven by formularies, step-therapy dynamics among NSAIDs, and payer preference for cost-effective NSAIDs and generic equivalents.
• Institutional purchasing: tends to favor lowest acquisition cost for non-protected molecules, reinforcing generic price compression.

How does regulatory and safety labeling shape market behavior?

Naproxen sodium carries class-wide NSAID risk and labeling content (gastrointestinal risk, cardiovascular risk considerations for NSAIDs, and contraindications). This affects market behavior in two direct ways:

• Physician and payer gatekeeping: higher-risk populations may shift toward alternative therapies or more conservative NSAID selection.
• OTC use guardrails: warnings, maximum daily dosing, and duration-of-use instructions influence adherence and repeat purchasing cycles.

These factors do not eliminate demand, but they reduce the ceiling for sustained premium and broaden the addressable base only for low-risk consumers and indications.

What drives competitive intensity and pricing for naproxen sodium?

The competitive set is primarily other oral NSAIDs. The biggest driver of pricing is not clinical superiority; it is generic availability and substitutability.

Competitive pressures

• Generic NSAIDs with comparable therapeutic targets
• Branded “flankers” and formulation variants that attempt to differentiate on speed of action or GI tolerance
• Cross-class substitution where prescribers and payers move patients to other NSAIDs under cost or tolerability constraints

Pricing implications

• The molecule’s long-established status creates a market where price follows cost-down cycles driven by manufacturing and distribution scale.
• Brand premiums remain limited and typically concentrate in periods when:
  • a proprietary formulation receives differentiation,
  • a class-wide product is in strong OTC rotation, or
  • channel promotions temporarily distort effective pricing.

What is the financial trajectory for naproxen sodium across its lifecycle?

Naproxen sodium shows the classic financial shape of an established generic-leaning drug:

1. Early branded build and differentiation via specific formulation advantages and physician adoption
2. Generic erosion as patents and exclusivities expire across markets
3. Stabilization at low net pricing with continued volume from OTC and prescription usage
4. Periodic share shifts tied to formulation, package promotions, and local reimbursement dynamics

Trajectory characteristics that matter to investors and operators

• Revenue growth is volume-led, not price-led in mature markets.
• Net revenue is sensitive to pack-price changes and retail promotional cycles for OTC products.
• Margin is distribution- and manufacturing-efficiency dependent, not differentiation dependent, once genericization dominates.

How do distribution and manufacturing economics translate into revenue and margins?

For a mature NSAID like naproxen sodium:

• Manufacturing scale lowers unit costs, which supports supply reliability and sustained market participation for multiple manufacturers.
• Pharmacy and wholesaler dynamics tend to compress margins for branded products first, then for remaining higher-cost SKUs.
• OTC rotation depends on shelf pricing and promotional cadence, so effective realized price can swing without affecting underlying prescription prevalence.

What investment-relevant market risks affect naproxen sodium financial outlook?

1) Strong substitutability

Any move in NSAID preference (payers, guidelines, safety perceptions) can shift share to competitors without increasing total NSAID market size.

2) Safety-driven prescribing constraints

Labeling and post-marketing experiences shift physician and payer behavior toward:

• more selective NSAID use,
• shorter duration strategies,
• and alternative therapies for higher-risk cohorts.

3) Pricing pressure from generic entry

The most direct financial risk is further fragmentation of supply that reduces realized net pricing, especially if multiple suppliers compete aggressively in OTC and prescription tender markets.

4) Regulatory or OTC schedule changes

Even when clinical demand remains steady, OTC accessibility rules, packaging requirements, and maximum dose instructions can alter purchase frequency and compliance.

What are the actionable market signals to track for naproxen sodium?

To forecast financial trajectory, operators typically monitor:

• OTC shelf share and price per unit by major retailers (effective pricing after promotions)
• Prescription volume trends by payer and formulary preference
• Channel mix shifts (OTC vs Rx) because OTC generally has higher marketing and promotional influence, while Rx is more payer-governed
• SKU mix changes (tablet vs liquid gel vs combination variants) since higher-cost formats can temporarily defend margin if shelf economics permit
• Generic cost-down events (new supply capacity, tender awards, and manufacturer expansions)

How do key historical drivers translate into current market dynamics?

Naproxen sodium is a long-established NSAID used for pain and inflammation. The market dynamics are dominated by:

• mature demand with chronic indication stability,
• high substitutability across NSAIDs,
• and generic competition that forces revenue growth to come from sustained volume and pack/channel execution rather than pricing power.

This produces a financial trajectory where:

• top-line stability depends on maintaining distribution reach and OTC visibility,
• profitability depends on cost efficiency and mix,
• and incremental growth typically comes from formulation-level and channel-level share gains rather than new medical adoption.

Key Takeaways

• Naproxen sodium operates in a mature NSAID category where generic penetration and cross-NSAID substitution cap pricing power.
• The financial trajectory is volume-led: stable baseline demand with share shifts driven by OTC shelf economics, prescription formularies, and SKU mix.
• Safety labeling and risk gatekeeping influence utilization intensity and shift demand toward lower-risk patient profiles and shorter-duration use.
• The most investable levers are channel execution (OTC promotion and pack strategy) and manufacturing/distribution cost leadership, not clinical differentiation alone.

FAQs

1. Is naproxen sodium revenue primarily driven by OTC or prescription?
   It depends on the geography and payer structure, but overall economics typically show a meaningful OTC contribution alongside steady prescription volume.

2. What most limits pricing power for naproxen sodium?
   Generic availability and strong substitution among NSAIDs compress realized prices and reduce brand premium sustainability.

3. Which product formats usually matter most to shelf economics?
   Tablets/caplets and liquid gels, since they influence onset positioning and effective pricing through pack and promotion strategy.

4. How do safety considerations affect demand?
   They reduce utilization intensity in higher-risk cohorts and shape prescriber and payer choices, impacting growth rate even if baseline pain demand persists.

5. What indicators best predict near-term financial performance?
   Retail effective pricing and shelf share for OTC, prescription volume by formulary tier, and SKU mix changes that alter realized margin.

References

[1] DailyMed. Naproxen Sodium. https://dailymed.nlm.nih.gov/
[2] U.S. Food and Drug Administration (FDA). NSAIDs: Information and Safety Considerations. https://www.fda.gov/
[3] World Health Organization (WHO). ATC/DDD Index: Anti-inflammatory and antirheumatic products, non-steroids (ATC group). https://www.whocc.no/